PI3K inhibitor combined with azacitidine for relapsed/refractory angioimmunoblastic T-cell lymphoma:a study of 5 cases
YANG Qin
LI Jia-qi
GENG Hong-zhi
ZENG Liang-yu
ZHANG Ying
MA Zhao-xia
ZONG Xiang-ping
CAI Wen-zhi
WU De-pei
LI Cai-xia
Abstract：Objective To investigate the efficacy and safety of PI3K inhibitors combined with azacitidine in the treatment of relapsed/refractory angioimmunoblastic T cell lymphoma(r/r AITL).Methods A retrospective analysis of the efficacy and safety of 5 r/r AITL patients treated by PI3K inhibitor combined with azacitidine in the Department of Hematology,the First Affiliated Hospital of Soochow University from March 2023 to November 2023.Results There were 3 male and 2 female among the five patients,with a median age of 58(range 50-86)years at diagnosis.All patients Ann Arbor stages were Ⅲ-Ⅳ,including three with bone marrow involvement,two experiencing relapsepost-autologous hematopoietic stem cell transplantation and three with EB virus infection.One or more gene mutations such as RHOA,IDH2,TET2,DNMT3A and EP300 were detected by Next-Generation Sequencing(NGS)in 4 patients.All five patients achieved remission,with 2 achieving complete response(CR)and 3achieving partial response(PR).The median follow-up was 286(153-397)days,andmedian progression free survival(PFS)and overall survival(OS)werenot reached.Adverse events were primarily grade 1-2,which were effectively controlled after supportive treatment,and no severe fatal adverse reactions occurred.Conclusion The patients with r/r AITL lacked effective rescue treatment options and had a poor prognosis,the PI3K inhibitor combined with azacitidine regimen successfully rescued five cases of r/r AITL with few adverse reactions and good tolerability,which is worthy of further promotion and application.
Keywords：PI3K inhibitorAzacitidinerelapsed/refractory angioimmunoblastic T-cell lymphomaefficacysafety
Publication Date：2024-10-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 861-865 )